Resolution TX Logo

Pioneering Regenerative Macrophage Therapy in Inflammatory and Fibrotic Diseases

Resolution is a clinical-stage biotechnology company pioneering Regenerative Macrophage Therapy in inflammatory and fibrotic diseases.

Inflammatory and fibrotic diseases affect millions of patients worldwide. We aim to treat these patients, for example by helping patients with liver cirrhosis avoiding the need for a transplantation.

The Science +

Regenerative Macrophage Therapy

Resolution Therapeutics is developing regenerative macrophage therapies to transform outcomes for people with inflammatory and fibrotic diseases. The Company is built upon more than a decade of work in the Founders’ laboratories at the University of Edinburgh, characterising the role of regenerative macrophages in organ repair, including the liver, both in the pre-clinical and clinical settings. Resolution’s world class team is focused on discovering, developing, manufacturing and taking to market regenerative macrophage therapies based on its proprietary platform of macrophage biology, cell engineering and manufacturing processes.

About us +

Our Patients

Our patient-centred approach drives everything we do. We are dedicated to developing therapies that make a real difference to people living with inflammatory and fibrotic diseases.

MORE INFO +

The Science

Our work builds on more than a decade of cutting-edge research demonstrating the therapeutic potential of macrophages in inflammatory and fibrotic diseases.

MORE INFO +

Publications

All the latest scientific publications underpinning our work by our scientific founders and groups.

MORE INFO +

Pipeline

Our pipeline builds on validated regenerative macrophage biology across two therapeutic approaches: an ex vivo cell therapy and next-generation in vivo programme.

MORE INFO +

About Us

Resolution is a clinical-stage biotechnology company pioneering Regenerative Macrophage Therapy in inflammatory and fibrotic diseases.

MORE INFO +

Careers

Interested in working on cutting-edge science in a fast-paced environment? We would love to hear from you.

MORE INFO +

Latest News

01/09/2026

Resolution Therapeutics partners with the Blood Centers of America, Inc. to support broad patient access to its experimental Regenerative Macrophage Therapy in the U.S.

Partnership will support Resolution’s pivotal clinical program in 2027, as well as future commercial preparedness for RTX001, its lead asset in patients with end-stage liver disease (ESLD) Primary goal is to ensure patients can access treatment in the community setting, where the majorityof decompensated patients are managed RTX001 has the potential to be the first treatment that demonstrates a clear and durable improvement in transplant free survival for ESLD patients

READ MORE +
25/08/2026

Nottingham is investigating a first-in-class cell treatment to help patients End Stage Liver Disease

Decompensated cirrhosis has a poor prognosis and few treatment options, with liver transplantation available to only a small minority of patients. Resolution Therapeutics is investigating RTX001, an engineered Regenerative Macrophage Therapy, as a potential alternative to improve survival and quality of life.

READ MORE +
18/08/2026

EMERALD Clinical Study: Q&A with Dr Paul Richardson & Dr Edward Britton, Royal Liverpool University Hospital

Dr Paul Richardson and Dr Edward Britton describes the End-Stage Liver Disease patient population being treated in the EMERALD clinical study which is evaluating Regenerative Macrophage Therapy as a potential new treatment.

READ MORE +
11/08/2026

The EMERALD clinical study: an overview with Prof. Ewan Forrest, Glasgow Royal Infirmary

EMERALD is an early-stage clinical trial of an innovative cell therapy for patients with end-stage liver disease, taking place in the UK and Spain. The therapy being tested, called Regenerative Macrophage Therapy, is designed to help even badly damaged livers recover, thus preventing disease from progressing further.

READ MORE +
06/08/2026

EMERALD Clinical Study: Q&A with Dr Kushala Abeysekera, Bristol Royal Infirmary Hospital

Liver disease kills over 12,000 people in the UK and 52,000 in the US every year. Once advanced, half of patients die within a year — and only 3% receive a transplant. Dr Kush Abeysekera explains why the status quo isn't working, and why Resolution Therapeutics is developing RTX001 as a potential alternative. First in a series on regenerative medicine in liver disease.

READ MORE +

CEO's Statement

Resolution is at the forefront of a new kind of cell therapy. We’re treating inflammatory organ disease with macrophages, the cells that the body uses to resolve injury and heal wounds. Our work builds on a huge body of science understanding the role of macrophages as orchestrators of the wound healing process; coupled with our world-leading founders, a top-quality scientific staff and proprietary insight into macrophage biology and manufacturing, we are poised to improve the lives of countless patients worldwide.

Amir Hefni CEO